Cancer Clinical Trial
Official title:
Evaluating Cancer Survivorship Care Models
The Evaluating Cancer Survivorship Care Models project is an innovative 3-year study that is
collecting data to help understand how to best deliver follow-up care to cancer survivors.
Cancer is a complex disease requiring complex treatments that can cause lasting impacts
after treatment ends. Some patients face physical, psychosocial, spiritual and/or practical
challenges as they adjust to life after cancer. Fortunately, health care providers have
begun to focus on the consequences of cancer and its treatment and are more actively working
with cancer survivors to manage post-treatment needs and care.
Led by the George Washington University and funded by the Patient-Centered Outcomes Research
Institute, this project brings together representatives from the Commission on Cancer, the
Cancer Support Community, LIVESTRONG and the American Cancer Society as well as cancer
survivors and healthcare professionals to better understand how different strategies or
models of care impact outcomes that are most important to cancer survivors. The project will
focus on survivors of breast, prostate and colorectal cancers and will be relevant for
understanding the needs and preferences of survivors of other cancers as well. The emphasis
is on patient-centered outcomes, which are outcomes that are most significant to patients,
such as patient satisfaction and quality of life.
Evaluating Cancer Survivorship Care Models Study Overview and Research Design
Cancer is a complex disease requiring complex treatments that can cause lasting impacts
after treatment ends. Some patients face lasting physical, psychosocial, spiritual and/or
practical challenges as they adjust to life after cancer. Fortunately, health care
clinicians have begun to focus on the consequences of cancer and its treatment and are more
actively working with cancer survivors to manage post-treatment needs and care.
The Evaluating Cancer Survivorship Care Models project is a groundbreaking 3-year
comparative effectiveness research (CER) study that examines how to best deliver follow-up
care to cancer survivors. This project is led by the George Washington University and funded
by the Patient-Centered Outcomes Research Institute. A key component of the project is the
use of a stakeholder Advisory Board chaired by a cancer survivor who serves as a senior
advisor to the research team. The Advisory Board includes survivors, survivor advocates,
clinicians, health care professionals and advisors from stakeholders across myriad facets of
cancer care, including the Cancer Support Community, LIVESTRONG, the Commission on Cancer,
and the American Cancer Society. These organizations are critical to the success of the
project.
The study is innovative in its focus on patient-centered outcomes. The first phase of the
project employed a mixed methods approach including a secondary analysis of existing data
from 4 national surveys, focus groups with cancer survivors, an environmental scan of
existing survivorship programs and a national survey of cancer survivors to develop an
outcomes tool and a prospective observational CER study. Based on results from the first
phase, the study team at the George Washington University (GW) developed a
patient-prioritized index to identify services and components of care that patients equate
with high quality survivorship care.
Three models of survivorship care at Commission on Cancer-accredited institutions were
identified through the environmental scan. In the CER phase of the study, each survivorship
care model will serve as a comparator for the other two models. Patients in the CER study
population will be adults who have been diagnosed with non-metastatic breast, prostate or
colorectal cancer and completed active treatment. Patient-reported outcomes will be assessed
at three points in the project: at baseline (immediately prior to and immediately following
a post-treatment survivorship visit), 3 months post-visit and 6 months post-visit.
Multivariable analyses including repeated measures and mixed-effect regression modeling will
be used to control for systematic differences across the groups, which would further
increase the validity of our results. Using the newly-developed index, the comparative
effectiveness study will measure the quality of programs according to what patients have
identified as most important to them.
The investigators have launched the CER phase of the study and are enrolling high-performing
survivorship programs. Our pool of invited participants consists of Commission on
Cancer-accredited sites with clinical survivorship care programs that meet the following
eligibility criteria:
- Provide services to survivors of breast, prostate or colorectal cancer
- Have demonstrated a high performance level on incorporating elements of survivorship
care into clinical care delivery
- See at least 60 new survivors yearly
- Includes the most common characteristics related to delivery of survivorship care
During the CER study, data will be gathered from survivorship program administrators,
patients and survivorship care clinicians. Survivorship program administrators will complete
an interview and survey to examine how survivorship programs are organized and identify key
characteristics of programs to determine which factors are most influential in delivering
high quality post-treatment survivorship care. Patients will complete surveys measuring
patient-centered outcomes: health-related quality of life; self-efficacy; satisfaction;
health care utilization and a newly developed measure of quality of survivorship care as
prioritized by patients. Clinicians will complete surveys on the services offered during
participating patients' initial post-treatment survivorship visit. Together, this data will
allow the GW study team to understand successful strategies for transforming the care
delivery system to be more responsive to patient needs.
In the third and final phase, this project will generate critical data for a variety of
decision-makers related to care for post-treatment cancer survivors and will result in
evidence-based guidance for how to organize and deliver post-treatment care. The GW study
team seeks to provide recommendations on survivorship care delivery best practices; develop
tools for improving survivorship programs and care delivery from both clinician and patient
perspectives; and to widely disseminate findings to a variety of stakeholders, including
survivors and their families, clinicians, survivorship care program leaders, payers,
policymakers and others.
;
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05346796 -
Survivorship Plan HEalth REcord (SPHERE) Implementation Trial
|
N/A | |
| Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
| Completed |
NCT04867850 -
Effect of Behavioral Nudges on Serious Illness Conversation Documentation
|
N/A | |
| Enrolling by invitation |
NCT04086251 -
Remote Electronic Patient Monitoring in Oncology Patients
|
N/A | |
| Completed |
NCT01285037 -
A Study of LY2801653 in Advanced Cancer
|
Phase 1 | |
| Completed |
NCT00680992 -
Study of Denosumab in Subjects With Giant Cell Tumor of Bone
|
Phase 2 | |
| Completed |
NCT00062842 -
Study of Irinotecan on a Weekly Schedule in Children
|
Phase 1 | |
| Active, not recruiting |
NCT04548063 -
Consent Forms in Cancer Research: Examining the Effect of Length on Readability
|
N/A | |
| Completed |
NCT04337203 -
Shared Healthcare Actions and Reflections Electronic Systems in Survivorship
|
N/A | |
| Recruiting |
NCT04349293 -
Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways
|
N/A | |
| Terminated |
NCT02866851 -
Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy
|
N/A | |
| Active, not recruiting |
NCT05304988 -
Development and Validation of the EFT for Adolescents With Cancer
|
||
| Completed |
NCT04448041 -
CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
|
||
| Completed |
NCT00340522 -
Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
|
||
| Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
| Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
| Completed |
NCT03109041 -
Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source
|
Phase 1 | |
| Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
| Terminated |
NCT01441115 -
ECI301 and Radiation for Advanced or Metastatic Cancer
|
Phase 1 | |
| Recruiting |
NCT06206785 -
Resting Energy Expenditure in Palliative Cancer Patients
|